Englewood-based , which was recently formed via a reverse merger, acquired ProstaScint, an imaging agent to help in the detection of prostate cancer, officials announced Tuesday.
Aytu (OTCMKTS: RSWN) acquired the rights to the commercial-state agent from Ireland-based .
Regulatory filings show that Aytu paid $1 million upfront with plans to pay more than $725,000 this year. The company also agreed to pay 8 percent of net sales after Oct. 31, 2017, up to a maximum of $2.5 million.
The transaction comes just two months after the formation of Aytu.
In April, Vyrix Pharmaceuticals Inc. and Luoxis Diagnostics — former subsidiaries of Englewood-based — acquired Loveland-based Rosewind Corp. and rebranded as Aytu. The new firm’s initial focus would be on urological and related conditions.
The merger incorporated assets that include Zertane, a late-stage treatment for premature ejaculation and the RedoxSYS System, a product that can evaluate redox potential, a measure of oxidants and reductants in a biological system.
Alicia Wallace: 303-954-1939, awallace@denverpost.com or twitter.com/aliciawallace
